Hepatitis a virus infection in Central-West Tunisia: an age structured model of transmission and vaccination impact.
Hepatitis A virus
Mathematical model
Public health
Seroprevalence
Vaccination
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
26 Aug 2020
26 Aug 2020
Historique:
received:
25
07
2019
accepted:
03
08
2020
entrez:
27
8
2020
pubmed:
28
8
2020
medline:
10
9
2020
Statut:
epublish
Résumé
The epidemiological pattern of hepatitis A infection has shown dynamic changes in many parts of the world due to improved socio-economic conditions and the accumulation of seronegative subjects, which leads to possible outbreaks and increased morbidity rate. In Tunisia, the epidemiological status of hepatits A virus is currently unknown. However, over the past years higher numbers of symptomatic hepatitis A virus infection in school attendants and several outbreaks were reported to the Ministry of Health, especially from regions with the lowest socio-economic levels in the country. The aim of this study was to investigate the current seroprevalence of hepatitis A virus antibodies in central-west Tunisia and assess the impact of hepatitis A virus vaccination on hepatitis A epidemiology. Serum samples from 1379 individuals, aged 5-75 years, were screened for hepatitis A virus antibodies. Adjusted seroprevalence, incidence and force of infection parameters were estimated by a linear age structured SEIR (Susceptible-Exposed-Infectious-Recovered) compartmental model. A vaccine model was then constructed to assess the impact on hepatitis A virus epidemiology of 3 scenarios of vaccination strategies: one dose at 12-months of age, one dose at 6-years and one dose at 12-months and another at 6-years of age during 6 years. A rapid increase in anti-hepatitis A virus seroprevalence was noted during infancy and adolescence: 47% of subjects under 10-years-old are infected; the prevalence increases to 77% at 15-years and reaches 97% in subjects aged 30-years. The force of infection is highest between 10 and 30-years of age and the incidence declines with increasing age. The vaccine model showed that the 3-scenarios lead to a significant reduction of the fraction of susceptibles. The two doses scenario gives the best results. Single-dose vaccination at 6-years of age provides more rapid decrease of disease burden in school-aged children, as compared to single-dose vaccination at 12-months, but keeps with a non-negligible fraction of susceptibles among children < 6-years. Our study confirms the epidemiological switch from high to intermediate endemicity of hepatitis A virus in Tunisia and provides models that may help undertake best decisions in terms of vaccinations strategies.
Sections du résumé
BACKGROUND
BACKGROUND
The epidemiological pattern of hepatitis A infection has shown dynamic changes in many parts of the world due to improved socio-economic conditions and the accumulation of seronegative subjects, which leads to possible outbreaks and increased morbidity rate. In Tunisia, the epidemiological status of hepatits A virus is currently unknown. However, over the past years higher numbers of symptomatic hepatitis A virus infection in school attendants and several outbreaks were reported to the Ministry of Health, especially from regions with the lowest socio-economic levels in the country. The aim of this study was to investigate the current seroprevalence of hepatitis A virus antibodies in central-west Tunisia and assess the impact of hepatitis A virus vaccination on hepatitis A epidemiology.
METHODS
METHODS
Serum samples from 1379 individuals, aged 5-75 years, were screened for hepatitis A virus antibodies. Adjusted seroprevalence, incidence and force of infection parameters were estimated by a linear age structured SEIR (Susceptible-Exposed-Infectious-Recovered) compartmental model. A vaccine model was then constructed to assess the impact on hepatitis A virus epidemiology of 3 scenarios of vaccination strategies: one dose at 12-months of age, one dose at 6-years and one dose at 12-months and another at 6-years of age during 6 years.
RESULTS
RESULTS
A rapid increase in anti-hepatitis A virus seroprevalence was noted during infancy and adolescence: 47% of subjects under 10-years-old are infected; the prevalence increases to 77% at 15-years and reaches 97% in subjects aged 30-years. The force of infection is highest between 10 and 30-years of age and the incidence declines with increasing age. The vaccine model showed that the 3-scenarios lead to a significant reduction of the fraction of susceptibles. The two doses scenario gives the best results. Single-dose vaccination at 6-years of age provides more rapid decrease of disease burden in school-aged children, as compared to single-dose vaccination at 12-months, but keeps with a non-negligible fraction of susceptibles among children < 6-years.
CONCLUSIONS
CONCLUSIONS
Our study confirms the epidemiological switch from high to intermediate endemicity of hepatitis A virus in Tunisia and provides models that may help undertake best decisions in terms of vaccinations strategies.
Identifiants
pubmed: 32842988
doi: 10.1186/s12879-020-05318-7
pii: 10.1186/s12879-020-05318-7
pmc: PMC7477833
doi:
Substances chimiques
Hepatitis A Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
627Subventions
Organisme : Ministry of Health and the Ministry of High Education and Scientific Research
ID : PRF-4; CIC2016IPT02
Références
Rev Epidemiol Sante Publique. 2017 Nov;65(6):437-442
pubmed: 29050813
Saudi J Kidney Dis Transpl. 2009 Mar;20(2):300-6
pubmed: 19237827
Rev Soc Bras Med Trop. 2005 Jul-Aug;38(4):285-9
pubmed: 16082472
Indian J Virol. 2012 Jun;23(1):29-35
pubmed: 23729999
Vaccine. 2000 Feb 18;18 Suppl 1:S65-7
pubmed: 10683552
MMWR Recomm Rep. 2006 May 19;55(RR-7):1-23
pubmed: 16708058
J Microbiol Immunol Infect. 2016 Oct;49(5):743-748
pubmed: 25442870
Hepat Mon. 2011 Apr;11(4):235-7
pubmed: 22087149
Ann Saudi Med. 2003 Nov-Dec;23(6):367-71
pubmed: 16868370
Pathol Biol (Paris). 2008 May;56(3):148-53
pubmed: 18178327
Vaccine. 2010 Sep 24;28(41):6653-7
pubmed: 20723630
Vaccine. 2007 Feb 26;25(10):1719-26
pubmed: 17229493
Vaccine. 2015 Jul 31;33(32):3813-20
pubmed: 26144899
J Infect Dis. 2013 Feb 1;207(3):493-6
pubmed: 23204169
J Viral Hepat. 2008 Oct;15 Suppl 2:47-50
pubmed: 18837834
J Infect Dis. 2003 Sep 1;188(5):671-7
pubmed: 12934183
Turk J Gastroenterol. 2014 Dec;25 Suppl 1:6-8
pubmed: 25910370
Niger Med J. 2014 Jul;55(4):279-84
pubmed: 25114360
Vaccine. 2016 Jan 20;34(4):555-562
pubmed: 26657185
Vaccine. 2014 Oct 21;32(46):6067-74
pubmed: 25236586
PLoS One. 2014 Feb 11;9(2):e87643
pubmed: 24523871
Korean J Hepatol. 2009 Dec;15(4):438-45
pubmed: 20037262
J Res Med Sci. 2014 Mar;19(Suppl 1):S56-63
pubmed: 25002897
PLoS One. 2013 Sep 17;8(9):e74752
pubmed: 24069343
Int Health. 2016 Mar;8(2):132-41
pubmed: 26163116
Int J Infect Dis. 2010 Feb;14(2):e115-20
pubmed: 19540786
BMC Infect Dis. 2007 Jul 04;7:73
pubmed: 17610736
Hum Vaccin Immunother. 2016 Dec;12(12):3160-3165
pubmed: 27532370
Hepat Mon. 2012 May;12(5):326-32
pubmed: 22783344
Int J Health Geogr. 2011 Oct 18;10:57
pubmed: 22008459
BMC Infect Dis. 2015 Oct 16;15:428
pubmed: 26471064
Int J Epidemiol. 2005 Jun;34(3):600-9
pubmed: 15831565
Epidemiol Rev. 2006;28:101-11
pubmed: 16775039
Am J Trop Med Hyg. 2005 Jul;73(1):40-3
pubmed: 16014829
JAMA. 1994 May 4;271(17):1328-34
pubmed: 8158817
Math Biosci. 1997 Oct 15;145(2):89-136
pubmed: 9309930
Am J Trop Med Hyg. 2005 Aug;73(2):453-6
pubmed: 16103621
Value Health. 2015 Jun;18(4):358-67
pubmed: 26091589
J Med Virol. 2015 Apr;87(4):569-74
pubmed: 25648328
Vaccine. 2008 Aug 18;26(35):4608-16
pubmed: 18597903
Wkly Epidemiol Rec. 2012 Jul 13;87(28/29):261–76
pubmed: 22905367
J Clin Virol. 2014 Jan;59(1):38-43
pubmed: 24332411
Eur J Epidemiol. 2008;23(1):45-53
pubmed: 17978852
Mem Inst Oswaldo Cruz. 2006 Mar;101(2):119-27
pubmed: 16830702
World J Gastroenterol. 2009 Jan 7;15(1):102-5
pubmed: 19115474
Microbiol Immunol. 2007;51(2):185-91
pubmed: 17310086
Trop Doct. 2008 Jan;38(1):65-6
pubmed: 18302878
Vaccine. 2006 Jul 7;24(27-28):5599-603
pubmed: 16757065
East Mediterr Health J. 2007 Nov-Dec;13(6):1256-64
pubmed: 18341176
Cad Saude Publica. 2016 Nov 01;32(11):e00175614
pubmed: 27982290
Vaccine. 2011 Aug 26;29(37):6259-61
pubmed: 21763745
Hum Vaccin Immunother. 2017 Aug 3;13(8):1942-1951
pubmed: 28481680
East Mediterr Health J. 2008 Sep-Oct;14(5):1028-35
pubmed: 19161074
Tunis Med. 2014 Mar;92(3):201-7
pubmed: 24955966